Skip to main content
Top
Published in: Strahlentherapie und Onkologie 12/2019

Open Access 01-12-2019 | Metastasis | Original Article

Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy

Results from a large multicenter cohort

Authors: Tilman Bostel, M.D., Robert Förster, Ingmar Schlampp, Tanja Sprave, Sati Akbaba, Daniel Wollschläger, Jürgen Debus, Arnulf Mayer, Heinz Schmidberger, Harald Rief, Nils Henrik Nicolay

Published in: Strahlentherapie und Onkologie | Issue 12/2019

Login to get access

Abstract

Purpose

This retrospective study aimed to evaluate the stability and fracture rates of osteolytic spinal bone metastases (SBM) in elderly patients following palliative radiotherapy (RT) and to derive prognostic factors for stability and survival.

Methods

A total of 322 patients aged at least 70 years received palliative RT at two major German academic medical centers or at the German Cancer Research Center. Stability assessment was based on the validated Taneichi score prior to RT and at 3 and 6 months after RT. The survival time following RT was assessed, and prognostic factors for stability and survival were analyzed.

Results

Prior to RT, 183 patients (57%) exhibited unstable SBM and 68 patients (21%) pathological fractures. At 3 and 6 months after RT, significant recalcification and stabilization were evident in 19% (23/118) and 40% (31/78) of surviving patients, respectively. Only 17 patients (5%) experienced new pathological fractures following RT. Tumor histology was found to significantly influence stabilization rates with only breast cancer patients exhibiting increased stabilization compared to patients with other histologies. The median survival time and 6‑month survival rates following RT were 5.4 months (95% confidence interval 4.4–7.2 months) and 48%, respectively. The patients’ performance status was found to be the strongest predictor for survival after RT in this patient cohort; further factors demonstrating a significant association with survival were the application of systemic treatment, the number of SBM and the primary tumor histology. To analyze the influence of age on survival after RT, study patients were stratified into 3 age groups (i.e., 70–74 years, 75–79 years, and ≥80 years). The subgroup of patients aged at least 80 years showed a strong trend towards a worse survival time following RT compared to younger patients (i.e., 6‑month survival rate 39% vs. 51%; p = 0.06, log-rank test).

Conclusions

Prognostic factors influencing overall survival such as performance status and histology should guide the choice for palliative RT for SBM. Strongly hypofractionated RT regimes may be advisable for most elderly patients considering the overall poor prognosis in order to reduce hospitalization times.
Literature
1.
go back to reference Vineis P, Wild CP (2014) Global cancer patterns: causes and prevention. Lancet 383:549–557CrossRef Vineis P, Wild CP (2014) Global cancer patterns: causes and prevention. Lancet 383:549–557CrossRef
2.
go back to reference Marosi C, Koller M (2016) Challenge of cancer in the elderly. Esmo Open 1:e20CrossRef Marosi C, Koller M (2016) Challenge of cancer in the elderly. Esmo Open 1:e20CrossRef
3.
go back to reference Aebi M (2003) Spinal metastasis in the elderly. Eur Spine J 12(Suppl 2):S202–S213CrossRef Aebi M (2003) Spinal metastasis in the elderly. Eur Spine J 12(Suppl 2):S202–S213CrossRef
4.
go back to reference Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11:1121–1131CrossRef Guise TA (2006) Bone loss and fracture risk associated with cancer therapy. Oncologist 11:1121–1131CrossRef
5.
go back to reference Schlampp I, Rieken S, Habermehl D et al (2014) Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol 190:792–797CrossRef Schlampp I, Rieken S, Habermehl D et al (2014) Stability of spinal bone metastases in breast cancer after radiotherapy: a retrospective analysis of 157 cases. Strahlenther Onkol 190:792–797CrossRef
6.
go back to reference Rief H, Bischof M, Bruckner T et al (2013) The stability of osseous metastases of the spine in lung cancer—a retrospective analysis of 338 cases. Radiat Oncol 8:200CrossRef Rief H, Bischof M, Bruckner T et al (2013) The stability of osseous metastases of the spine in lung cancer—a retrospective analysis of 338 cases. Radiat Oncol 8:200CrossRef
7.
go back to reference Chow S, Ding K, Wan BA et al (2017) Patient reported outcomes after radiation therapy for Bone metastases as a function of Age: a secondary analysis of the NCIC CTG SC-twenty-three randomized trial. Am J Hospice Palliat Med 35(4):718–723CrossRef Chow S, Ding K, Wan BA et al (2017) Patient reported outcomes after radiation therapy for Bone metastases as a function of Age: a secondary analysis of the NCIC CTG SC-twenty-three randomized trial. Am J Hospice Palliat Med 35(4):718–723CrossRef
8.
go back to reference Nieder C, Angelo K, Haukland E, Pawinski A (2014) Survival after palliative radiotherapy in geriatric cancer patients. Anticancer Res 34:6641–6645PubMed Nieder C, Angelo K, Haukland E, Pawinski A (2014) Survival after palliative radiotherapy in geriatric cancer patients. Anticancer Res 34:6641–6645PubMed
9.
go back to reference Rades D, Conde AJ, Garcia R et al (2015) A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. Radiat Oncol 10:173CrossRef Rades D, Conde AJ, Garcia R et al (2015) A new instrument for estimation of survival in elderly patients irradiated for metastatic spinal cord compression from breast cancer. Radiat Oncol 10:173CrossRef
10.
go back to reference Rades D, Evers JN, Rudat V, Bajrovic A, Karstens JH, Schild SE (2014) A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. BMC Cancer 14:589CrossRef Rades D, Evers JN, Rudat V, Bajrovic A, Karstens JH, Schild SE (2014) A validated score estimating ambulatory status following radiotherapy of elderly patients for metastatic spinal cord compression. BMC Cancer 14:589CrossRef
11.
go back to reference Nakamura N, Shikama N, Wada H et al (2012) Patterns of practice in palliative radiotherapy for painful bone metastases: a survey in Japan. Int J Radiat Oncol Biol Phys 83:e117–20CrossRef Nakamura N, Shikama N, Wada H et al (2012) Patterns of practice in palliative radiotherapy for painful bone metastases: a survey in Japan. Int J Radiat Oncol Biol Phys 83:e117–20CrossRef
12.
go back to reference Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436CrossRef Chow E, Harris K, Fan G, Tsao M, Sze WM (2007) Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 25:1423–1436CrossRef
13.
go back to reference Lutz S, Berk L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976CrossRef Lutz S, Berk L, Chang E et al (2011) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965–976CrossRef
14.
go back to reference Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S (1997) Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine 22:239–245CrossRef Taneichi H, Kaneda K, Takeda N, Abumi K, Satoh S (1997) Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine 22:239–245CrossRef
15.
go back to reference Bostel T, Forster R, Schlampp I et al (2017) Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy. Radiat Oncol 12:115CrossRef Bostel T, Forster R, Schlampp I et al (2017) Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy. Radiat Oncol 12:115CrossRef
16.
go back to reference Sprave T, Hees K, Bruckner T et al (2018) The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol 13:134CrossRef Sprave T, Hees K, Bruckner T et al (2018) The influence of fractionated radiotherapy on the stability of spinal bone metastases: a retrospective analysis from 1047 cases. Radiat Oncol 13:134CrossRef
17.
go back to reference Foerster R, Habermehl D, Bruckner T et al (2014) Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol 9:194CrossRef Foerster R, Habermehl D, Bruckner T et al (2014) Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival. Radiat Oncol 9:194CrossRef
18.
go back to reference Foerster R, Hees K, Bruckner T et al (2018) Survival and stability of patients with Urothelial cancer and spinal Bone metastases after palliative radiotherapy. Radiol Oncol 52:189–194CrossRef Foerster R, Hees K, Bruckner T et al (2018) Survival and stability of patients with Urothelial cancer and spinal Bone metastases after palliative radiotherapy. Radiol Oncol 52:189–194CrossRef
19.
go back to reference Bostel T, Forster R, Schlampp I et al (2016) Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy. Tumori 102:156–161CrossRef Bostel T, Forster R, Schlampp I et al (2016) Stability, prognostic factors and survival of spinal bone metastases in malignant melanoma patients after palliative radiotherapy. Tumori 102:156–161CrossRef
20.
go back to reference Salvatore G, Berton A, Giambini H et al (2018) Biomechanical effects of metastasis in the osteoporotic lumbar spine: a finite element analysis. BMC Musculoskelet Disord 19:38CrossRef Salvatore G, Berton A, Giambini H et al (2018) Biomechanical effects of metastasis in the osteoporotic lumbar spine: a finite element analysis. BMC Musculoskelet Disord 19:38CrossRef
21.
go back to reference Pagani S, Fini M, Giavaresi G, Salamanna F, Borsari V (2015) The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone 79:176–182CrossRef Pagani S, Fini M, Giavaresi G, Salamanna F, Borsari V (2015) The active role of osteoporosis in the interaction between osteoblasts and bone metastases. Bone 79:176–182CrossRef
22.
go back to reference Schlampp I, Lang H, Forster R et al (2015) Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy. Tumori 101:614–620CrossRef Schlampp I, Lang H, Forster R et al (2015) Stability of spinal bone metastases and survival analysis in renal cancer after radiotherapy. Tumori 101:614–620CrossRef
23.
go back to reference Bollen L, Jacobs WCH, Van der Linden YM, Van der Hel O, Taal W, Dijkstra PDS (2018) A systematic review of prognostic factors predicting survival in patients with spinal bone metastases. Eur Spine J 27:799–805CrossRef Bollen L, Jacobs WCH, Van der Linden YM, Van der Hel O, Taal W, Dijkstra PDS (2018) A systematic review of prognostic factors predicting survival in patients with spinal bone metastases. Eur Spine J 27:799–805CrossRef
24.
go back to reference Bollen L, van der Linden YM, Pondaag W et al (2014) Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro-oncology 16:991–998CrossRef Bollen L, van der Linden YM, Pondaag W et al (2014) Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients. Neuro-oncology 16:991–998CrossRef
25.
go back to reference Westhoff PG, de Graeff A, Monninkhof EM et al (2014) An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases. Int J Radiat Oncol Biol Phys 90:739–747CrossRef Westhoff PG, de Graeff A, Monninkhof EM et al (2014) An easy tool to predict survival in patients receiving radiation therapy for painful bone metastases. Int J Radiat Oncol Biol Phys 90:739–747CrossRef
26.
go back to reference van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW, Dutch Bone Metastasis Study Group (2005) Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 103:320–328CrossRef van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW, Dutch Bone Metastasis Study Group (2005) Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer 103:320–328CrossRef
27.
go back to reference Rades D, Evers JN, Bajrovic A, Veninga T, Karstens JH, Schild SE (2014) Metastatic spinal cord compression: a validated survival score for elderly patients. Strahlenther Onkol 190:919–924CrossRef Rades D, Evers JN, Bajrovic A, Veninga T, Karstens JH, Schild SE (2014) Metastatic spinal cord compression: a validated survival score for elderly patients. Strahlenther Onkol 190:919–924CrossRef
28.
go back to reference Koswig S, Budach V (1999) Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 175:500–508CrossRef Koswig S, Budach V (1999) Remineralization and pain relief in bone metastases after after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 175:500–508CrossRef
29.
go back to reference Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384CrossRef Weber JS, D’Angelo SP, Minor D et al (2015) Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16:375–384CrossRef
30.
go back to reference Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRef Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540–1550CrossRef
31.
go back to reference Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRef Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723CrossRef
32.
go back to reference Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O (2018) Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer 6:26CrossRef Elias R, Giobbie-Hurder A, McCleary NJ, Ott P, Hodi FS, Rahma O (2018) Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J Immunother Cancer 6:26CrossRef
33.
go back to reference Daste A, Domblides C, Gross-Goupil M et al (2017) Immune checkpoint inhibitors and elderly people: A review. Eur J Cancer 82:155–166CrossRef Daste A, Domblides C, Gross-Goupil M et al (2017) Immune checkpoint inhibitors and elderly people: A review. Eur J Cancer 82:155–166CrossRef
Metadata
Title
Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy
Results from a large multicenter cohort
Authors
Tilman Bostel, M.D.
Robert Förster
Ingmar Schlampp
Tanja Sprave
Sati Akbaba
Daniel Wollschläger
Jürgen Debus
Arnulf Mayer
Heinz Schmidberger
Harald Rief
Nils Henrik Nicolay
Publication date
01-12-2019
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 12/2019
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-019-01482-1

Other articles of this Issue 12/2019

Strahlentherapie und Onkologie 12/2019 Go to the issue